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effort, resources and the participation of a huge team
made up of a multitude of highly trained medical
specialists, such as cardiac surgeons, cardiologists,
cardiac anaesthetists, cardiac intensivists and many
others, who often have dedicated their entire
professional lives to this exciting field of medicine.
Far from claiming to be a thorough and exhaustive
expos￩ on CHD, this article rather aims to present to
medical students from everywhere in the world an
overview of the nature of this important disease and of
its global impact. We will provide a definition of CHD,
highlight a few examples, give a summary of its
epidemiology, and finally summarize the history of the
study and treatment modalities. Our focus will also be
on the inequalities in the treatment of CHD between the
western world and developing nations. Finally, the
challenges that must be addressed to truly improve care
around the world will be presented.
DEFINITION OF CONGENITAL HEART
DISEASE
What is congenital heart disease? Simply put, one
could say that it is a developmental malformation of the
heart started during fetal development and present at
birth, which results in abnormal anatomy and
physiology of the heart, has a profound deleterious
impact on the other organs and structures of the body
and adversely affects the health of the child.
Embryologically, it results from a multitude of factors,
*To whom correspondence should be addressed:
Christo I. Tchervenkov, M.D.
The Montreal Children’s Hospital
Cardiovascular Surgery,
2300, Tupper street, Room C-829
Montreal, Quebec, Canada
H3H 1P3
Email: ctchervenkov@wspchs.org
Website: www.wspchs.org
INTRODUCTION
Medical schools teach their students about anatomy,
histology, cell biology, genetics, embryology,
physiology, biochemistry, pathophysiology,
pharmacology, and other subdivisions of the medical
knowledge and know-how. Despite acquiring this
complex science and having the opportunity to interact
with patients in the clinical setting, very rarely do
medical students gather a global understanding of what
impact a disease represents on a personal, societal and
global level. Congenital heart disease (CHD) is a
condition that is present in approximately 1 in 100
births, has a remarkable heterogeneity and complexity
and has a significant impact on the child’s survival and
quality of life if left untreated. Even when the initial
congenital defect is successfully repaired, patients with
CHD require a lifelong follow-up and the possibility of
subsequent reinterventions. Physicians are involved
from the beginning to the end with the diagnosis,
counselling, every step of the treatment and the lifelong
follow-up. The treatment of CHD requires an enormous186 McGill Journal of Medicine 2008
most of them unknown, which lead to abnormalities in
the in-utero development of the fetal heart.
Anatomically, CHD comprises a huge number of
cardiac malformations from the simplest to the most
complex, characterized by extreme heterogeneity,
which alter the normal and optimal structure and
function of the heart and of other organs in the body.
Every part of the heart and great vessels can be
involved and malformed. The atria, ventricles, the great
vessels, the atrioventricular and semilunar valves, and
the coronary arteries can be affected to various degrees
depending on the specific heart malformation present.
The many deleterious consequences affecting other
organs further complicate CHD. As a whole, CHD can
be present in many forms and across the entire age
spectrum; from the blue newborn baby with profound
cyanosis due to transposition of the great arteries to the
old adult with progressive fatigue due to a previously
undiagnosed atrial septal defect coming to medical
attention with overt heart failure. Although considered
by many a rare disease, CHD is the most common
congenital illness and presents a significant burden to
the children of this world and to mankind.
CHILDREN OF THE WORLD AFFECTED BY
CONGENITAL HEART DISEASE
Globally, approximately 130 million babies are born
every year. It is said that CHD affects approximately
0.8% of all live births. Simple calculations indicate that
approximately 1 million babies are born each year with
CHD and 90% of those newborns see the world in areas
of the globe where access to appropriate medical care is
either difficult or impossible. One can estimate that of
the 280 000 babies who die each year from a congenital
cardiac anomaly in the neonatal period, more than 250
000 are not offered the care that has been available over
the past half-century and that has allowed cardiac
surgeons and cardiologists from around the world to
save countless lives, very often with fairly simple
measures [1].
Listing every congenital lesion affecting the human
heart is far beyond the scope of this paper. However, it
is interesting to briefly ponder upon the natural history
of some of those malformations to understand
adequately their significance. The progression and
severity of the disease is specific to every lesion and
present in a wide spectrum. For example, individuals
with large atrial septal defects face a risk of mortality of
5-15% before the age of 30 years. Similarly, the
presence of a patent ductus arteriosus is associated with
a 30% risk of mortality before the age of one year and a
42% risk of death before 45 years of age. Of all the
individuals born with tetralogy of Fallot with
pulmonary stenosis, 25% will die within their first year
of life if left untreated. 40%, 70%, and 95% will be
dead, respectively, by the age of 3, 10, and 40 years.
Looking at more complex pathologies, transposition of
the great arteries is associated, all varieties considered,
with a 45%, 85%, and 90% mortality at one month, 6
months and one year respectively. Finally, hypoplastic
left heart syndrome, which is the fourth most common
congenital cardiac defect, results in the mortality of
most neonates within one to two weeks of birth and
survival beyond 6 weeks of age is unusual [2].
CHD is a major burden to the children of this world.
However, despite being rather revealing, the mortality
rates stated above do not give an accurate rendering of
the misery children and young adults with CHD face.
Indeed, the morbidity ensuing from unrepaired CHD is
difficult to truly gauge and quantify but is immensely
important. Therefore, one must consider with equal
magnitude the decreased quality of life faced by those
individuals. Suffering from frequent pulmonary
infections, a high risk of bacterial endocarditis, chronic
cyanosis, the risk of neurological events and decreased
functional status, the existence of a child surviving with
unrepaired CHD is far from normal and optimal.
HISTORY OF DIAGNOSIS AND TREATMENT
OF CONGENITAL HEART DISEASE
In 1936, Dr. Maude Abbott (1869-1940), of McGill
University in Montreal, published her famous Atlas of
congenital cardiac disease. This work, proposing the
first classification system for CHD, was based on her
lifelong study of the clinical and post-mortem records
of more than 1000 cases of cardiac malformations. The
Atlas rapidly became the main international reference in
CHD and Maude Abbott has since been considered the
founder of the systematic study of CHD [3]. The
development of the study of congenital cardiac disease
quickly flourished thereafter. Maverick surgeons now
remembered for their great sense of innovation paved
the way to the successful treatment of CHD. An
important milestone in the treatment of CHD was the
development of a palliative operation to alleviate the
profound cyanosis in patients with tetralogy of Fallot.
This was the result of a historic collaboration between
Alfred Blalock, Helen Taussig and Vivien Thomas, with
the advent of the systemic pulmonary shunt bearing
their name. However, the single most important step in
the treatment of CHD was the invention of the heart-
lung machine by John Gibbon Jr of Jefferson Medical
College in Philadelphia who spent 20 year working on
its development and was the first to use it successfully
in a human in 1953. Subsequently, with the pioneering
efforts of physicians and surgeons it soon becameImprove Congenital Heart Disease 187 Vol. 11 No. 2
possible to repair even complex cardiac malformations
and consequently impact on the life of millions of
children. Steady progress in diagnostic modalities, in
surgical techniques, in establishment of new
procedures, as well as improvement in preoperative
care, intra-operative anaesthesia and perfusion
management and intensive post-operative care have
resulted in significant reduction in mortality and
morbidity. Major improvement in early and late survival
for CHD also ensued. Complex malformations such as
transposition of the great arteries, tetralogy of Fallot,
and hypoplastic left heart syndrome can now be treated
with real optimism for the future lives of the afflicted
children. However, much work needs to be done with
the rapidly increasing number of adults with CHD and
the realization of the long-term problems in many of the
“repaired” CHD patients.
CURRENT STATUS IN TREATMENT FOR
CONGENITAL HEART DISEASE
While we have some information regarding the status
of congenital cardiac care in NorthAmerica and the rest
of the western world, little is known about the precise
situation in the remainder of the globe.
Indeed, data published in 2005 by Jacobs and al. in the
Report of the 2005 Society of Thoracic Surgeons
Congenital Heart Surgery Practice and Manpower
Survey gives a good picture of the state of our specialty
in North America. At the time of the survey, there were
248 congenital cardiac surgeons in the United States of
America and 15 in Canada. Each group is respectively
distributed amongst 121 and 8 surgical centres. The
average age of a congenital cardiac surgeon in North
America is 48.3 years and, on average, surgeons have
9.2 years of post-graduate training. Only 4% of all
congenital cardiac surgeons in North America are
females. Based on those numbers, there is
approximately one congenital cardiac surgeon per 1.5-2
millions population [4].
This information is available concerning North
America, but data is scarce regarding the rest of the
world. To palliate to this situation, the World Society for
Pediatric and Congenital Heart Surgery
(www.wspchs.org) embarked on a fact-finding mission
in 2007. Preliminary results from the survey conducted
confirm an important inconsistency between the various
regions of the world. While western countries enjoy a
proportion of approximately 1 congenital cardiac
surgeon per 1.5-2 million inhabitants, our survey shows
very different ratios in SouthAmerica,Asia, andAfrica;
respectively 1 : 6 million, 1 : 25 million, and 1 : 38
million. Quick calculations, which are obviously
limited by their inaccuracy and the imprecise nature of
the data from which they are based on, indicate that the
developing world is in need of approximately 1 000 to
1 500 additional congenital cardiac surgeons. This is a
gross estimate which is, nonetheless, very revealing.
The data currently being gathered by the World
Society is showing that the patterns of practice are
otherwise quite similar on the five continents. Indeed,
the average age, the proportions of males and females,
and the duration of post-graduate training of congenital
cardiac surgeons are quite comparable across the board.
However, the funding sources of congenital cardiac
surgery programs vary. In the United States, for
example, most units are privately funded. However, in
the rest of the world, it appears that government sources
are the main financial supporters of congenital cardiac
surgery centers. This information is incomplete and the
World Society is planning to pursue its fact-finding
effort in this regard.
The most important component of the treatment of
CHD is teamwork. The concerted input of many
specialists, i.e. surgeons, cardiologists, intensivists,
anesthesiologists, perfusionists, nurses is needed.
Although in a congenital cardiac surgery program the
surgeon often assumes a leadership role, the
collaboration of all is essential to its success. Indeed,
the necessary diagnostic modalities, such as
echocardiography, angiography, computerized
tomography, or magnetic resonance imaging are often
difficult to evaluate and require the analytical and
judgment skills of specifically trained physicians. The
same is true for the intra-operative management of the
patients. Indeed, cardiac anesthesiologists and
perfusionists with specialized training in the care of
children with congenital cardiac disease carry the
utmost importance. This concept carries over to the
intensive care unit with the post-operative care of the
patients. The treatment of CHD is very complex and
necessitates the work of many highly skilled
individuals, a high level of organization and logistics
and appropriate financial support
CHALLENGES TO IMPROVEMENT OF
CARDIAC CARE FOR CONGENITAL HEART
DISEASE ACROSS THE WORLD
For an obvious reason of lack of resources, the
development of pediatric and congenital heart surgery
around the world has been late, slow and erratic in most
developing countries. Competing priorities, poor
structural organizations, lack of financial resources,
lack of trained personnel and absence of stable training
and educational infrastructure are among the many
reasons for this unfortunate situation. While some
countries have succeeded in developing surgical
programs to treat CHD, most children born with a
cardiac malformation still do not have access to188 McGill Journal of Medicine 2008
appropriate medical and surgical care.
To palliate to this complete or relative absence of
access to cardiac surgical care in many countries,
different projects have emerged. This help takes many
forms and it is safe to say that the perfect model does
not exist yet. Most of this work is funded by charitable
organizations and helps children with CHD on a small
scale. Some groups bring children in need to North
America or Europe so that they can undergo surgery and
then return to their country of origin. This has been
largely inefficient due to the great cost and effort
required and has only helped very few children.
Humanitarian surgical missions consisting of cardiac
surgeons, cardiologists, intensivists, anesthesiologists,
perfusionists, and nurses visit countries for a few weeks
at a time with the goals to operate children in need of
surgery as well as to form surgical teams and hopefully
launch congenital cardiac surgery programs which can
flourish and progress in a sustainable fashion. Finally,
some areas have seen the establishment of cardiac
centres after the local training of their healthcare
professionals or their return from instruction abroad.
Surgeons, cardiologists, anaesthesiologists, intensivists
and other professionals trained internationally infinitely
enrich their countries upon their return. However, a
serious problem is the lack of retention due to the poor
local infrastructure and critical mass of health care
professionals, which further exacerbates the vicious
circle. By and large these efforts have so far had a
minimal impact in the numbers of children treated
compared to the overall needs.
All the efforts described above have to be concerted
and the various groups interested in globally improving
congenital cardiac care around the world have to meet
and organize themselves to reach their goal in a
sustainable fashion.TheWorld Society for Pediatric and
Congenital Heart Surgery aims to provide this forum. It
is of paramount importance to identify the most
profitable, practical, and cost-efficient way to help the
children of the world with CHD.
Indeed, while we do intensive research and strive to
decrease our mortality rates by fractions of percentage
points in the western world, the vast majority of
children born with CHD still have an unacceptably high
risk of mortality. The progress of the last decades has
been largely limited to the developed world.
Consequently, every year approximately 90 % of more
than 1 000 000 children born with CHD across the
world receive either suboptimal care or are totally
denied care.
Although CHD has not been on the radar screen of
most global health agencies and humanitarian
organizations so far and since there has been little focus
on the global epidemiology of pediatric and congenital
cardiac disease, considerable work remains to be done
if one is to try to significantly improve cardiac care
around the globe.
WORLD SOCIETY FOR PEDIATRIC AND
CONGENITAL HEART SURGERY: LEADING
THE WAY IN A NEW PARADIGM SHIFT FOR
THE GLOBAL IMPROVEMENT OF CARE
The idea for a global organization was first discussed
in 2004 in Montreal during an international meeting of
pediatric and congenital heart surgeons scheduled
during the Centennial Celebrations of the Montreal
Children’s Hospital under the leadership of Christo I.
Tchervenkov, Professor of Surgery at McGill
University. The World Society for Pediatric and
Congenital Heart Surgery was then established in 2006.
During his Presidential Address at the Inaugural
Meeting of Washington DC in May 2007, the World
Society President, Christo I. Tchervenkov from
Montreal, Canada, presented his vision for the role of
the World Society and talked about the key elements for
the global improvement of care. President Tchervenkov
coined the phrase “Medicine of RESPECT” or
“Medicine of Responsible Education Sustained through
Partnership, Empowerment, Care and Commitment,
and Teamwork and Trust” as the basis of the necessary
paradigm shift required for the global improvement of
care in the 21st century [5].
The World Society for Pediatric and Congenital Heart
Surgery is in an exceptional position to truly improve
care for pediatric and congenital cardiac disease across
the world. Being the largest society for pediatric and
congenital heart surgery in the world with more than
500 members from close to 70 countries, its potential
for playing a defining role in the global improvement of
care is significant. The vision of the World Society is
that every child born anywhere in the world with a
congenital heart defect should have access to
appropriate medical and surgical care. Its mission is to
promote the highest quality comprehensive cardiac care
to all patients with pediatric and/or congenital heart
disease, from the fetus to the adult, regardless of the
patient’s economic means, with an emphasis on
excellence in education, research and community
service.The vision and mission of theWorld Society are
being pursued by working towards clearly defined
objectives in the following domains: patient care,
training and education, research, and community
service. In the area of patient care, the World Society
hopes to promote the professional and educational
development of surgeons specializing and practicing
pediatric and congenital heart surgery across the world,
as well as the dissemination of informational support to
patients, parents of patients, families of patients, and189 Vol. 11 No. 2 Delay in Diagnosis of TB in the Monteregie region
health care professionals, working in collaboration with
societies such as the International Society for
Nomenclature of Pediatric and Congenital Heart
Disease. It also wants to develop global standards for
the training and education of pediatric and congenital
heart surgeons and for the practice of pediatric and
congenital heart surgery. Finally, its members
originating from all areas of the globe will form a forum
for the respectful exchange of knowledge in the form of
scientific meetings and publications across the world
Finally, and maybe most importantly, the World
Society aims to foster collaboration across medical and
surgical subspecialties and is working toward the
establishment of a multi-societal Global Organization
for Pediatric and Congenital Heart Disease. This
Organization has seen birth in June 2008, in Montreal,
with the proclamation of a resolution for its
establishment at the World Summit on Pediatric and
Congenital Heart Surgery Services, Education and
Cardiac Care in Children and Adults with Congenital
Heart Disease taking place in Montreal from June 19-
22, 2008. Composed of multiple professional
associations of surgeons, cardiologists, intensivists,
anaesthesiologists, nurses, and perfusionists, this
Global Organization will be the cornerstone of the
large-scale improvement of congenital cardiac care
around the world.
CONCLUSION
It is our hope that this article will give a good
overview of the nature of CHD, of its global impact and
of the challenges that inevitably need to be addressed in
order to truly impact on the future on innumerable
children around the world. Every speciality concerned
by CHD need to be empowered and embark on this
journey to globally improve our services to children of
countless developing countries.
Congenital cardiac surgery has evolved enormously
over the last 60 years since the pioneering work of
Abbott, Blalock, Taussig, Gibbons, Lillehei, Kirklin,
Castaneda and others. It has matured to a point where it
enjoys unprecedented successes with results barely
conceivable only a few decades ago. However, only a
small proportion of the children born yearly with CHD
benefit from those successes. The world needs a major
paradigm shift in the care for pediatric and congenital
cardiac disease. The field of congenital cardiac surgery
does not need any new major scientific discovery. There
is rather a need to share with the rest of the world what
has already been discovered and implemented over the
last half-century. A hand needs to be extended to those
in the developing world. Such major improvement in
care can only result from the systematic organization of
all health care providers across the world, based on the
concept of a Medicine of RESPECT, or the Respectful
Education Sustained through Partnership,
Empowerment, Care, Commitment, Teamwork, and
Trust [5].
Medical students, being where they are in their
training, should hopefully be influenced and
enlightened by the facts previously described. Their
open-mindedness, optimistic view of the world, and
indefectible enthusiasm represent perhaps what is
needed to truly advance this agenda. The objectives that
the World Society for Pediatric and Congenital Heart
Surgery has given itself are numerous and broad and
will likely have a real impact on the remaining 90% of
children born with CHD who are not offered treatment.
However, the process we have embarked on will be long
and arduous and may be filled with many frustrations. It
will not be a sprint, or even a marathon, but perhaps
more of a long arduous triathlon. Nevertheless, we have
taken the first few steps on this challenging and exciting
journey.TheWorld Society for Pediatric and Congenital
Heart Surgery and the soon to be established Global
Organization for Pediatric and Congenital Heart
Disease are in a unique position to lead the way in this
seemingly daunting task. We sincerely welcome the
input of all medical students and strongly encourage all
of those interested to participate, in one way or another,
in their upcoming careers or academic projects, to the
furthering of this somewhat grandiose, but, in our
opinion, noble and realistic endeavour.
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